Methylprednisolone NDC 62135-763

NDC codes

FDA NDC Directory

Product NDC (as listed)62135-763Labeler and product segments. Claims need a package NDC.

Product NDC at billing width62135-0763Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
62135-763-26	62135076326	25 TABLET in 1 BOTTLE (62135-763-26)Marketed from May 14, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Methylprednisolone
Generic name (nonproprietary): methylprednisolone
Active ingredients: Methylprednisolone — 32 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Chartwell RX, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 209097
Marketing start: Feb 22, 2019
Listing expires: Dec 31, 2026
Other FDA classes: Corticosteroid Hormone Receptor Agonists (Mechanism)
Identifiers: Product ID 62135-763_225669c1-9479-52eb-e063-6394a90a649bSPL ID 225669c1-9479-52eb-e063-6394a90a649bSPL set ID bdd048bb-7e6c-45c7-b51a-075e83ca9f5bRxCUI 197969, 197971, 197973, 259966, 328161UNII X4W7ZR7023UPC 0362135763268, 0362135760212, 0362135761264, 0362135762506, 0362135760014, 0362135759308
Pharmacologic class: Corticosteroid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N462135076326 followed by a unit qualifier and the quantity

Package 62135-0763-26. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 17, 2024.

Indications (excerpt from the label)

INDICATIONS AND USAGE Methylprednisolone tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 209097

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 209097
Product	Strength	Form · route	Labeler	Product NDC
Methylprednisolone	Methylprednisolone 2 mg/1	TabletOral	Chartwell RX, LLC	62135-759
Methylprednisolone	Methylprednisolone 16 mg/1	TabletOral	Chartwell RX, LLC	62135-762
Methylprednisolone	Methylprednisolone 4 mg/1	TabletOral	Chartwell RX, LLC	62135-760
Methylprednisolone	Methylprednisolone 8 mg/1	TabletOral	Chartwell RX, LLC	62135-761